Get the Stockscreener App
1.20
30.43%
0.28
After Hours:
1.23
0.03
+2.50%
Predictive Oncology Inc stock is traded at $1.20, with a volume of 3.88M.
It is up +30.43% in the last 24 hours and up +46.38% over the past month.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
See More
Previous Close:
$0.92
Open:
$0.95
24h Volume:
3.88M
Relative Volume:
22.87
Market Cap:
$8.00M
Revenue:
$1.52M
Net Income/Loss:
$-13.97M
P/E Ratio:
-0.3934
EPS:
-3.05
Net Cash Flow:
$-13.29M
1W Performance:
+21.21%
1M Performance:
+46.38%
6M Performance:
+18.81%
1Y Performance:
-64.50%
1-Day Range:
$0.89
$1.53
1-Week Range:
$0.77
$1.53
52-Week Range:
$0.55
$3.76
Predictive Oncology Inc Stock (POAI) Company Profile
Name
Predictive Oncology Inc
Sector
Industry
Phone
412-432-1500
Address
91 43RD STREET, PITTSBURGH, MN
Compare POAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
POAI
Predictive Oncology Inc
|
1.20 | 8.00M | 1.52M | -13.97M | -13.29M | -3.05 |
|
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Predictive Oncology Inc Stock (POAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
Predictive Oncology Inc Stock (POAI) Latest News
OSUR Stock Surges Over 5% Amid Market Activity - GuruFocus.com
Intelligent Bio Solutions (NASDAQ:INBS) Stock Quotes, Forecast and News Summary - Benzinga
Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with 29.4% CAGR | MarketsandMarkets - The Malaysian Reserve
Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with 29.4% CAGR | MarketsandMarkets™ - PR Newswire UK
BullFrog AI Announces Appointment of Chief Financial Officer - The Manila Times
Addressing the oncological ‘other’: How predictive analysis can shift the research imbalance - pharmaphorum
Head to Head Contrast: Predictive Oncology (NASDAQ:POAI) vs. Avitar (OTCMKTS:AVTI) - Defense World
Certis Oncology Solutions Unveils CertisOI Assistant™ - Business Wire
Predictive Oncology explores strategic options to enhance value By Investing.com - Investing.com Canada
Predictive Oncology explores strategic options to enhance value - Investing.com India
Predictive Oncology engaged in ‘productive discussions’ with multiple parties - TipRanks
Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic Alternatives - The Manila Times
Predictive Oncology Advances Strategic Sale Talks, Touts 150K+ Tumor Sample Portfolio - StockTitan
Predictive Oncology Inc.'s (NASDAQ:POAI) Path To Profitability - Simply Wall St
Bluejay Diagnostics (NASDAQ:BJDX) Stock Quotes, Forecast and News Summary - Benzinga
Predictive Oncology faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Predictive Oncology faces Nasdaq delisting over equity shortfall - Investing.com India
Predictive Oncology Receives Notice of Non-Compliance from Nasdaq - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
This SolarEdge Technologies Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Predictive Oncology downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Predictive Oncology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Predictive Oncology Inc. Reports Q3 2024 Earnings - TipRanks
U.S. STOCKS BankUnited, Natera, Adaptimmune - XM
Artificial Intelligence in Drug Discovery Market Expecting Huge Demand in Upcoming Years - openPR
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update - The Manila Times
Predictive Oncology Reports Q3 Loss, Launches Strategic Review Amid 49% Revenue Drop | POAI Stock News - StockTitan
Predictive Oncology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
International Conference on the Crystallization of Biological Macromolecules - Arizona State University (ASU)
American Well Corporation (AMWL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets™ - PR Newswire UK
Some Major Key Players In The Genomic Cancer Panel and Profiling Market: - InsightAce Analytic
AngioDynamics (ANGO) Stock Dips Amidst Financial Performance Rev - GuruFocus.com
, a machine learning-based RNA oncology test predicting immunotherapy response - Business Wire
HC Wainwright & Co. Initiates Coverage of Predictive Oncology (POAI) with Buy Recommendation - MSN
Artificial Intelligence in Genomics Market is Estimated to Reach $5.5 Billion By 2032 - 대구포스트
POAI stock touches 52-week low at $0.64 amid market challenges By Investing.com - Investing.com South Africa
Predictive Oncology Inc (POAI) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
POAI stock touches 52-week low at $0.64 amid market challenges - Investing.com
Certis files patent for AI platform to ID predictive cancer biomarkers - BioWorld Online
ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors - The Cancer Letter
HBIO Stock Drops Amidst Market Fluctuations - GuruFocus.com
POAI stock touches 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
POAI stock touches 52-week low at $0.74 amid market challenges - Investing.com India
BioAI Announces Strategic Partnership with Arbele Bio to advance Predictive AI-Models in Oncology Clinical Trials - PR Newswire
ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors - The Cancer Letter
11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex
Predictive Oncology (NASDAQ:POAI) Shares Pass Below Two Hundred Day Moving Average of $1.42 - Defense World
Payoneer Global (NASDAQ:PAYO) Reaches New 52-Week High at $7.67 - MarketBeat
Strong Market Opportunities For OneStream Amid Rising Demand for AI-Driven Financial Solutions, Analyst Says - Yahoo Finance UK
Predictive Oncology Inc Stock (POAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):